Phase 3 study of TW001 in patients with Amyotrophic Lateral Sclerosis

Trial Profile

Phase 3 study of TW001 in patients with Amyotrophic Lateral Sclerosis

Planning
Phase of Trial: Phase III

Latest Information Update: 02 Dec 2015

At a glance

  • Drugs Edaravone (Primary)
  • Indications Amyotrophic lateral sclerosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Dec 2015 New trial record
    • 01 Dec 2014 According to a Treeway B.V. media release, TW001 received orphan drug designation from European Medicines Agency (EMA) for the treatment of Amyotrophic Lateral Sclerosis (ALS).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top